These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 30807895)
1. Design, synthesis and biological study of hybrid drug candidates of nitric oxide releasing cucurbitacin-inspired estrone analogs for treatment of hepatocellular carcinoma. Abou-Salim MA; Shaaban MA; Abd El Hameid MK; Elshaier YAMM; Halaweish F Bioorg Chem; 2019 Apr; 85():515-533. PubMed ID: 30807895 [TBL] [Abstract][Full Text] [Related]
2. Utilizing Estra-1,3,5,16-Tetraene Scaffold: Design and Synthesis of Nitric Oxide Donors as Chemotherapeutic Resistance Combating Agents in Liver Cancer. Abou-Salim MA; Shaaban MA; Abd El Hameid MK; Alanazi MM; Halaweish F; Elshaier YAMM Molecules; 2023 Mar; 28(6):. PubMed ID: 36985726 [TBL] [Abstract][Full Text] [Related]
3. Cucurbitacins inspired organic synthesis: Potential dual inhibitors targeting EGFR - MAPK pathway. Mahnashi M; Elgazwi SM; Ahmed MS; Halaweish FT Eur J Med Chem; 2019 Jul; 173():294-304. PubMed ID: 31022583 [TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of pyrazolo[3,4-d]pyrimidines: Nitric oxide releasing compounds targeting hepatocellular carcinoma. Elshaier YAMM; Shaaban MA; Abd El Hamid MK; Abdelrahman MH; Abou-Salim MA; Elgazwi SM; Halaweish F Bioorg Med Chem; 2017 Jun; 25(12):2956-2970. PubMed ID: 28487127 [TBL] [Abstract][Full Text] [Related]
5. Hybrid molecule from O2-(2,4-dinitrophenyl)diazeniumdiolate and oleanolic acid: a glutathione S-transferase π-activated nitric oxide prodrug with selective anti-human hepatocellular carcinoma activity and improved stability. Fu J; Liu L; Huang Z; Lai Y; Ji H; Peng S; Tian J; Zhang Y J Med Chem; 2013 Jun; 56(11):4641-55. PubMed ID: 23617697 [TBL] [Abstract][Full Text] [Related]
6. JS-K, a nitric oxide prodrug, induces DNA damage and apoptosis in HBV-positive hepatocellular carcinoma HepG2.2.15 cell. Liu Z; Li G; Gou Y; Xiao D; Luo G; Saavedra JE; Liu J; Wang H Biomed Pharmacother; 2017 Aug; 92():989-997. PubMed ID: 28605880 [TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and biological evaluation of novel hybrids targeting mTOR and HDACs for potential treatment of hepatocellular carcinoma. Zhai S; Zhang H; Chen R; Wu J; Ai D; Tao S; Cai Y; Zhang JQ; Wang L Eur J Med Chem; 2021 Dec; 225():113824. PubMed ID: 34509167 [TBL] [Abstract][Full Text] [Related]
8. Synthesis and anti-hepatocellular carcinoma activity of novel O Zou Y; Yan C; Liu JC; Huang ZJ; Xu JY; Zhou JP; Zhang HB; Zhang YH Chin J Nat Med; 2017 Dec; 15(12):928-937. PubMed ID: 29329650 [TBL] [Abstract][Full Text] [Related]
9. Design, molecular docking, in vitro, and in vivo studies of new quinazolin-4(3H)-ones as VEGFR-2 inhibitors with potential activity against hepatocellular carcinoma. Eissa IH; Ibrahim MK; Metwaly AM; Belal A; Mehany ABM; Abdelhady AA; Elhendawy MA; Radwan MM; ElSohly MA; Mahdy HA Bioorg Chem; 2021 Feb; 107():104532. PubMed ID: 33334586 [TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and cytotoxic evaluation of nitric oxide-releasing derivatives of isosteviol. Liu Y; Wang T; Ling Y; Bao N; Shi W; Chen L; Sun J Chem Biol Drug Des; 2017 Sep; 90(3):473-477. PubMed ID: 28122177 [TBL] [Abstract][Full Text] [Related]
11. Novel anticancer oridonin derivatives possessing a diazen-1-ium-1,2-diolate nitric oxide donor moiety: Design, synthesis, biological evaluation and nitric oxide release studies. Xu S; Wang G; Lin Y; Zhang Y; Pei L; Yao H; Hu M; Qiu Y; Huang Z; Zhang Y; Xu J Bioorg Med Chem Lett; 2016 Jun; 26(12):2795-2800. PubMed ID: 27158140 [TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological evaluation of novel nitric oxide-donating protoberberine derivatives as antitumor agents. Chen J; Wang T; Xu S; Lin A; Yao H; Xie W; Zhu Z; Xu J Eur J Med Chem; 2017 May; 132():173-183. PubMed ID: 28359045 [TBL] [Abstract][Full Text] [Related]
13. Indoline ureas as potential anti-hepatocellular carcinoma agents targeting VEGFR-2: Synthesis, in vitro biological evaluation and molecular docking. Eldehna WM; Fares M; Ibrahim HS; Aly MH; Zada S; Ali MM; Abou-Seri SM; Abdel-Aziz HA; Abou El Ella DA Eur J Med Chem; 2015 Jul; 100():89-97. PubMed ID: 26071861 [TBL] [Abstract][Full Text] [Related]
14. Biological screening of cucurbitacin inspired estrone analogs targeting mitogen-activated protein kinase (MAPK) pathway. Ahmed MS; El-Senduny F; Taylor J; Halaweish FT Chem Biol Drug Des; 2017 Sep; 90(3):478-484. PubMed ID: 28171685 [TBL] [Abstract][Full Text] [Related]
15. Novel nitric oxide-releasing derivatives of farnesylthiosalicylic acid: synthesis and evaluation of antihepatocellular carcinoma activity. Ling Y; Ye X; Zhang Z; Zhang Y; Lai Y; Ji H; Peng S; Tian J J Med Chem; 2011 May; 54(9):3251-9. PubMed ID: 21504204 [TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and antitumor evaluation of novel histone deacetylase inhibitors equipped with a phenylsulfonylfuroxan module as a nitric oxide donor. Duan W; Li J; Inks ES; Chou CJ; Jia Y; Chu X; Li X; Xu W; Zhang Y J Med Chem; 2015 May; 58(10):4325-38. PubMed ID: 25906087 [TBL] [Abstract][Full Text] [Related]
17. Novel series of 6-(2-substitutedacetamido)-4-anilinoquinazolines as EGFR-ERK signal transduction inhibitors in MCF-7 breast cancer cells. Ismail RSM; Abou-Seri SM; Eldehna WM; Ismail NSM; Elgazwi SM; Ghabbour HA; Ahmed MS; Halaweish FT; Abou El Ella DA Eur J Med Chem; 2018 Jul; 155():782-796. PubMed ID: 30047410 [TBL] [Abstract][Full Text] [Related]
18. JS-K, a novel non-ionic diazeniumdiolate derivative, inhibits Hep 3B hepatoma cell growth and induces c-Jun phosphorylation via multiple MAP kinase pathways. Ren Z; Kar S; Wang Z; Wang M; Saavedra JE; Carr BI J Cell Physiol; 2003 Dec; 197(3):426-34. PubMed ID: 14566972 [TBL] [Abstract][Full Text] [Related]
19. Keshari AK; Singh AK; Raj V; Rai A; Trivedi P; Ghosh B; Kumar U; Rawat A; Kumar D; Saha S Drug Des Devel Ther; 2017; 11():1623-1642. PubMed ID: 28615927 [TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological evaluation of novel ferrocene-pyrazole derivatives containing nitric oxide donors as COX-2 inhibitors for cancer therapy. Ren SZ; Wang ZC; Zhu D; Zhu XH; Shen FQ; Wu SY; Chen JJ; Xu C; Zhu HL Eur J Med Chem; 2018 Sep; 157():909-924. PubMed ID: 30149323 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]